par Schoenen, Jean;Monseu, Guy;Pierre, Ph;Vanderlinden, C.;Sautois, D.;Vandenberghe, Alain;Bulcke, Jan A L J.;Caekebeke, Jo F V J.;Dehaene, Ides;De Keyser, Jacques;Hildebrand, G.;Joffroy, Alfred 
;Laloux, Patrice;Louis, Paul
Référence Cephalalgia, 14, 1, page (55-63)
Publication Publié, 1994
;Laloux, Patrice;Louis, PaulRéférence Cephalalgia, 14, 1, page (55-63)
Publication Publié, 1994
Article révisé par les pairs
| Résumé : | In a multicenter open longitudinal clinical trial where 479 patients suffering from migraine with or without aura were recruited, patients treated at home one to three migraine attacks with their customary treatment, and subsequently, over a 3‐month period, one to three migraine attacks with (5 mg sumatriptan sc using an auto‐injector. The headache response to customary treatment was 19% at 1 h and 30.5% at 2 h, and was not significantly different when only attacks treated “adequately” according to accepted treatment recommendations were considered: 16% at 1 h and 35% at 2 h. In contrast, 69% and 82% of patients treated with 6 mg sumatriptan sc had mild headache or no headache at 1 and 2 h respectively, regardless of migraine type or duration of symptoms prior to treatment. Other migraine symptoms (nausea, vomiting, photo‐ and phonophobia) were effectively treated with sumatriptan. Recurrence of migraine was observed in 31% of patients and was well controlled by a second injection of sumatriptan. It is concluded that 6 mg sumatriptan sc, self‐administered using an auto‐injector, is well tolerated and more effective than most currently used acute treatments for migraine in a population of severely affected patients consulting a neurologist. Copyright © 1994, Wiley Blackwell. All rights reserved |
